Literature DB >> 15016347

Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Lorinda Chung1, Paul J Utz.   

Abstract

Scleroderma is an autoimmune disease involving endothelial cell damage and fibroblast overproduction of extracellular matrix. Several autoantibodies present in the sera of patients with scleroderma, including anti-endothelial cell, antifibroblast, anti-matrix metalloproteinase, and antifibrillin-1 antibodies, may directly contribute to disease pathogenesis. Scleroderma also is characterized by the presence of antinuclear and antinucleolar antibodies, which correlate with particular phenotypes. These include antitopoisomerase-I, anticentromere, antihistone, anti-polymyositis/scleroderma, anti-Th/To, anti-U3-small nucleolar ribonucleoprotein particle, anti-U1-small nuclear ribonucleoprotein particle, anti-RNA polymerase, and anti-B23 antibodies. Other antibodies classically associated with other autoimmune diseases, such as antiphospholipid, antineutrophil cytoplasmic, and antimitochondrial antibodies, also have been described in patients with scleroderma. This review will summarize the various autoantibodies associated with scleroderma, their putative pathogenic roles, and their phenotypic correlations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016347     DOI: 10.1007/s11926-004-0061-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  48 in total

1.  Antibodies to beta2 glycoprotein I and cardiolipin in SSc.

Authors:  L Schoenroth; M Fritzler; L Lonzetti; J-L Senécal
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis.

Authors:  C M Antonioli; E Danieli; P Airò; R Cattaneo; A Tincani
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

3.  Quantitative genetic variation in CD19 expression correlates with autoimmunity.

Authors:  S Sato; M Hasegawa; M Fujimoto; T F Tedder; K Takehara
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

4.  Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases.

Authors:  M Kuwana; K Kimura; M Hirakata; Y Kawakami; Y Ikeda
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

5.  Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension.

Authors:  Danielle B Ulanet; Fredrick M Wigley; Allan C Gelber; Antony Rosen
Journal:  Arthritis Rheum       Date:  2003-02-15

Review 6.  Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.

Authors:  Michelle L Harris; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

7.  Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.

Authors:  Dhanita Khanna; Amita Aggarwal; Darshan S Bhakuni; Rajeshwar Dayal; Ramnath Misra
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

8.  Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.

Authors:  Carlo Chizzolini; Elena Raschi; Roger Rezzonico; Cinzia Testoni; Roberto Mallone; Armando Gabrielli; Andrea Facchini; Nicoletta Del Papa; Maria Orietta Borghi; Jean Michel Dayer; Pier Luigi Meroni
Journal:  Arthritis Rheum       Date:  2002-06

9.  A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.

Authors:  Ghaith M Mitri; Mary Lucas; Noreen Fertig; Virginia D Steen; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2003-01

10.  Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis.

Authors:  H Endo; T Hosono; H Kondo
Journal:  J Rheumatol       Date:  1994-05       Impact factor: 4.666

View more
  20 in total

1.  Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.

Authors:  Chao-Jun Hu; Guang Song; Wei Huang; Guo-Zhen Liu; Chui-Wen Deng; Hai-Pan Zeng; Li Wang; Feng-Chun Zhang; Xuan Zhang; Jun Seop Jeong; Seth Blackshaw; Li-Zhi Jiang; Heng Zhu; Lin Wu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2012-05-30       Impact factor: 5.911

Review 2.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

3.  Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.

Authors:  Yasmin Akbarali; Jennifer Matousek-Ronck; Laura Hunt; Leslie Staudt; Morris Reichlin; Joel M Guthridge; Judith A James
Journal:  J Autoimmun       Date:  2007-01-08       Impact factor: 7.094

4.  Exon-1 polymorphism of ctla-4 gene is not associated with systemic sclerosis in Iranian patients.

Authors:  A Rajaee; A Ebrahimi; A Fotouhi Ghiam; T Kalantari; A Ghaderi
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

Review 5.  [Scleroderma associated autoantibodies - clinical and diagnostic relevance].

Authors:  R Mierau; E Genth
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

6.  Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

Authors:  D James Haddon; Hannah E Wand; Justin A Jarrell; Robert F Spiera; Paul J Utz; Jessica K Gordon; Lorinda S Chung
Journal:  J Rheumatol       Date:  2017-03-15       Impact factor: 4.666

Review 7.  The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.

Authors:  Nicole H Kattah; Michael G Kattah; Paul J Utz
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

Review 8.  Toll-like receptor driven B cell activation in the induction of systemic autoimmunity.

Authors:  Nathaniel M Green; Ann Marshak-Rothstein
Journal:  Semin Immunol       Date:  2011-04       Impact factor: 11.130

9.  Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III.

Authors:  Murray Baron; Marie Hudson; Solène Tatibouet; Russell Steele; Ernest Lo; Sabrina Gravel; Geneviève Gyger; Tarek El Sayegh; Janet Pope; Audrey Fontaine; Ariel Masetto; Debora Matthews; Evelyn Sutton; Norman Thie; Niall Jones; Maria Copete; Dean Kolbinson; Janet Markland; Getulio Nogueira; David Robinson; Marvin Fritzler; Mervyn Gornitsky
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

10.  Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Fu Jun Li; Ranu Surolia; Huashi Li; Zheng Wang; Tejaswini Kulkarni; Gang Liu; Joao A de Andrade; Daniel J Kass; Victor J Thannickal; Steven R Duncan; Veena B Antony
Journal:  J Immunol       Date:  2017-07-28       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.